Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 9, 2005 - Issue 1
Submit an article Journal homepage
57
Views
17
CrossRef citations to date
0
Altmetric
Review

The vascular endothelium in diabetes: a practical target fordrug treatment?

Karen L Andrews RMIT University, Microvascular Biology Group, School of Medical Sciences, Bundoora, Victoria 3083, Australia. [email protected]
,
Malarvannan Pannirselvam Heart & Stroke/Richard Lewar Centre, University Health Network (General Division) & University of Toronto Fitzgerald Building, 100 College St, Toronto, Ontario M5S 3E2 Canada. [email protected]
,
Todd J Anderson University of Calgary and the Smooth Muscle Research Group, Department of Medicine, University of Calgary, Calgary, Alberta, T2N 4N1, Canada. [email protected]
,
Alicia J Jenkins St Vincent’s Hospital, Department of Medicine, Fitzroy, 3065, Melbourne, Australia. [email protected]
,
Chris R Triggle RMIT University, Microvascular Biology Group, School of Medical Sciences, RMIT University, Bundoora, Victoria 3083, Australia. [email protected]
&
Michael A Hill Department of Physiology and Pharmacology, University of New South Wales, Kensington, NSW 2052, Australia. [email protected]
Pages 101-117 | Published online: 22 Apr 2005

Bibliography

  • KANNEL WB, MCGEE DL: Diabetes and cardiovascular risk factors: the Framingham study. Circulation (1979) 59(1):8–13.
  • STAMLER J, VACCARO O, NEATON JD, WENTWORTH D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care (1993) 16(2):434–444.
  • LEE WL, CHEUNG AM, CAPE D, ZINMAN B: Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care (2000) 23(7):962–968.
  • HSUEH WA, QUINONES MJ: Role of endothelial dysfunction in insulin resistance. Am. J. Cardiol. (2003) 92(4A):10J–17J.
  • DEEDWANIA PC: Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr. Diab. Rep. (2003) 3(4)289–292.
  • KAWANO H, MOTOYAMA T, HIRASHIMA O et al.: Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J. Am. Coll. Cardiol (1999) 34(1):146–154.
  • THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng]. J. Med. (1993) 329(14):977–986.
  • UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia (1991) 34(12):877–890.
  • •[7] and [8] are classical large population-based studies clearly defining a relationship between hyperglycaemia and the progressive development of vascular complications in diabetic subjects. Further, the benefit of intensive metabolic control is emphasised.
  • HAIRE-JOSHU D, GLASGOW RE, TIBBS TL: Smoking and diabetes. Diabetes Care (1999) 22(11):1887–1898.
  • WATTS GF, O'BRIEN SF, SILVESTER W, MILLAR JA: Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Li. (1996) 91(5):567–573.
  • DANDONA P, ALJADA A, BANDYOPADHYAY A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Iminunol (2004) 25(1):4–7.
  • VLASSARA H, PALACE MR: Diabetes and advanced glycation end products. ./. Intern. Med. (2002) 251(2):87–101.
  • NISHIKAWA T, EDELSTEIN D, DU XL et al.: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 404(6779):787–790.
  • •This paper provides a unifying hypothesis linking several biochemical abnormalities in diabetes (increased PKC activity, accumulation of advanced glycation end products and increased activity of the aldose reductase pathway) to mitochondrial superoxide production. Previously, investigators have largely concentrated on the role of these pathways as independent factors.
  • DOGRA G, RICH L, STANTON K, WATTS GF: Endothelium-dependent and independent vasodilation studies at normoglycaemia in Type I diabetes mellitus with and without microalbuminuria. Diabetologia (2001) 44(5):593–601.
  • TOOKE JE, GOH KL: Vascular function in Type 2 diabetes mellitus and prediabetes: the case for intrinsic endotheiopathy. Diabet. Med. (1999) 16(9):710–715.
  • PLAYFORD D, WATTS GF: Endothelial dysfunction, insulin resistance and diabetes: exploring the web of causality. Aust. NZI. Med. (1999) 29(4):523–534.
  • ENGERMAN RL, KERN TS: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes (1987) 36(7):808–812.
  • FIORETTO P, STEFFES MW, SUTHERLAND DE, GOETZ FC, MAUER M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl. J. Med. (1998) 339(2):69–75.
  • EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (EDIC) RESEARCH GROUP: Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes (1999) 48(2):383–390.
  • Epidemiology of diabetes intervention and complications (EDIC): Effect of intensive therapy on the microvascular complications of Type 1 diabetes mellitus. "AMA (2002) 287(19):2563–2569.
  • DAVIS MJ, HILL MA: Signalling mechanisms underlying the vascular myogenic response. Physic] Rev (1999) 79(2):387–423.
  • MARTINEZ-LEMUS LA, WU X, WILSON E et al.: Integrins as unique receptors for vascular control. Vasc. Res. (2003) 40(3):211–233.
  • AIRD WC: Endothelium as an organ system. Grit. Care Med. (2004) 32(5 Suppl.):5271–5279.
  • MCGUIRE JJ, DING H, TRIGGLE CR: Endothelium-derived relaxing factors: a focus on endothelium-derived hyperpolarizing factor(s). Can. J. Physic] Pharmacol (2001) 79(6):443–470.
  • VANHOUTTE PM: Endothelium-dependent hyperpolarizations: the history. Pharmacol Res. (2004) 49(6)503–508.
  • BUSSE R, EDWARDS G, FELETOU M et al: EDHF: bringing the concepts together. Trends Pharmacol Sci. (2002) 23(8):374–380.
  • SANDOW SL: Factors, fiction and endothelium-derived hyperpolarizing factor. Clin. Exp. Pharmacol Physic] (2004) 31(9):563–570.
  • DING H, TRIGGLE CR: Relaxing blood vessels: Are there novel endothelium-dependent mediators to be found and can their discovery lead to the development of new therapeutic agents? Pharmaceutical News (2001) 8:42–49.
  • FELETOU M, VANHOUTTE PM: EDHF: new therapeutic targets? Pharmacol Res. (2004) 49(6):565–580.
  • MICHIELS C: Endothelial cell functions. J. Cell. Physiol (2003) 196(3):430–443.
  • DE VRIESE AS, VERBEUREN TJ, VAN DE VOORDE J, LAMEIRE NH, VANHOUTTE PM: Endothelial dysfunction in diabetes. BE J. Pharinacol (2000) 130(5):963–974.
  • PANNIRSELVAM M, ANDERSON TJ, TRIGGLE CR: Endothelial cell dysfunction in Type I and II diabetes: the cellular basis for dysfunction. Drug Dev. Res. (2003) 58:28–41.
  • TRIGGLE CR, HOLLENBERG M, ANDERSON TJ et al: The endothelium in health and disease-a target for therapeutic intervention. J. Smooth Muscle Res. (2003) 39(6):249–267.
  • PIEPER GM, SIEBENEICH W, DONDLINGER LA: Short-term oral administration of L-arginine reverses defective endothelium-dependent relaxation and cGMP generation in diabetes. Eur. Pharmacol (1996) 317(2-3):317–320.
  • HEITZER T, KROHN K, ALBERS S, MEINERTZ T: Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia (2000) 43(11):1435–1438.
  • PANNIRSELVAM M, SIMON V, VERMA S, ANDERSON T, TRIGGLE CR: Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. Br. J. Pharmacol (2003) 140(4):701–706.
  • ALP NJ, CHANNON KM: Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler. Thromb. Vasc. Biol. (2004) 24(3):413–420.
  • WEBER LP, MACLEOD KM: Influence of streptozotocin diabetes on the alpha-1 adrenoceptor and associated G proteins in rat arteries. .1 Pharmacol Exp. Ther. (1997) 283(3):1469–1478.
  • SOBREVIA L, MANN GE: Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Exp. Physic] (1997) 82 (3) :423–452.
  • GAZIS A, WHITE DJ, PAGE SR, COCKCROFT JR: Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabet. Med. (1999) 16(4):304–311.
  • TESFAMARIAM B, COHEN RA: Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am. Physic] (1992) 263(2 Pt 2):H321–H326.
  • OGITA H, LIAO J: Endothelial functionand oxidative stress. Endothelium (2004) 11(2):123–132.
  • ENDEMANN DH, SCHIFFRIN EL: Nitric oxide, oxidative excess, and vascular complications of diabetes mellitus. Curr. Hypertens. Rep. (2004) 6(2):85–89.
  • TESFAMARIAM B, BROWN ML, DEYKIN D, COHEN RA: Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. .1 Clin. Invest. (1990) 85(3):929–932.
  • TESFAMARIAM B, COHEN RA: Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am. Physiol (1992) 262(6 Pt 2):H1915–H1919.
  • SHIMIZU K, MURAMATSU M, KAKEGAWA Y et al.: Role of prostaglandin H2 as an endothelium-derived contracting factor in diabetic state. Diabetes (1993) 42(9):1246–1252.
  • LAGAUD GJ, MASIH-KHAN E, KAI S, VAN BREEMEN C, DUBE GP: Influence of Type II diabetes on arterial tone and endothelial function in murine mesenteric resistance arteries. J. Vasc. Res. (2001) 38(6):578–589.
  • MCVEIGH GE, BRENNAN GM, JOHNSTON GD et al: Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia (1992) 35(8):771–776.
  • LEKAKIS J, PAPAMICHAEL C, ANASTASIOU H et al.: Endothelial dysfunction of conduit arteries in insulin-dependent diabetes mellitus without microalbuminuria. Cardiovasc. Res. (1997) 34(1):164–168.
  • CLARKSON P, CELERMAJER DS, DONALD AE et al: Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J. Am. Coll. Cardiol (1996) 28(3):573–579.
  • DE VRIESE AS, VAN DE VOORDE J, BLOM HJ et al.: The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate. Diabetologia (2000) 43(9):1116–1125.
  • PIEPER GM: Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia (1999) 42(2):204–213.
  • FUKAO M, HATTORI Y, KANNO M, SAKUMA I, KITABATAKE A: Alterations in endothelium-dependent hyperpolarization and relaxation in mesenteric arteries from streptozotocin-induced diabetic rats. Br. J. Pharmacol (1997) 121(7): 1383–1391.
  • PANNIRSELVAM M, VERMA S, ANDERSON TJ, TRIGGLE CR: Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/clb -I-) mice: role of decreased tetrahydrobiopterin bioavailability. BE Pharmacol (2002) 136(2):255–263.
  • PANES J, KUROSE I, RODRIGUEZ-VACA D et al: Diabetes exacerbates inflammatory responses to ischaemia-reperfusion. Circulation (1996) 93(1):161–167.
  • MCLEOD DS, LEFER DJ, MERGES C, LUTTY GA: Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am. J. Pathol (1995) 147(3):642–653.
  • KARIO K, MATSUO T, KOBAYASHI H et al.: Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler. Thromb. Vasc. Biol. (1995) 15(8):1114–1120.
  • COOPER ME, BONNET F, OLDFIELD M, JANDELEIT-DAHM K: Mechanisms of diabetic vasculopathy: an overview. Am. J. Hypertens. (2001) 14(5 Pt 1):475–486.
  • BASTA G, SCHMIDT AM, DE CATERINA R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. (2004) 63(4):582–592.
  • ZENON GJ, 3rd, ABOBO CV, CARTER BL, BALL DW: Potential use of aldose reductase inhibitors to prevent diabetic complications. Chit. Pharm. (1990) 9(6):446–457.
  • GIUGLIANO D, CERIELLO A, PAOLISSO G: Oxidative stress and diabetic vascular complications. Diabetes Care (1996) 19(3):257–267.
  • CRAVEN PA, STUDER RK, NEGRETE H, DERUBERTIS FR: Protein kinase C in diabetic nephropathy. J. Diabetes Complications (1995) 9(4):241–245.
  • EVANS JL, GOLDFINE ID, MADDUX BA, GRODSKY GM: Oxidative stress and stress-activated signalling pathways: a unifying hypothesis of Type 2 diabetes. Endocr. Rev (2002) 23(5):599–622.
  • EVANS JL, GOLDFINE ID, MADDUX BA, GRODSKY GM: Are oxidative stress-activated signalling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes (2003) 52(0:1–8.
  • COOPER ME, CAO Z, RUMBLE JR et al: Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies. Metabolism (1998) 47(12 Suppl. 0:24–27.
  • BONNET F, CAO Z, COOPER ME et al.: Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. Diabetes Metab. (2003) 29(4 Pt 0:386–392.
  • LANDER HM, TAURAS JM, OGISTE JS et al.: Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. (1997) 272(28):17810–17814.
  • BROWNLEE M: Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 414(6865):813–820.
  • BISHARA NB, DUNLOP ME, MURPHY TV et al.: Matrix protein glycation impairs agonist-induced intracellular Ca2' signalling in endothelial cells. ./. Cell. Physiol (2002) 193(1):80–92.
  • KUHLMANN CR, SCHAFER M, LI F et al.: Modulation of endothelial Ca(2-0-activated KH channels by oxidized LDL and its contribution to endothelial proliferation. Cardiovasc. Res. (2003) 60(3):626–634.
  • SHEETZ MJ, KING GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA (2002) 288(20):2579–2588.
  • CALLES-ESCANDON J, CIPOLLA M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev (2001) 22 (1):36–52.
  • HILL MA, EGE EA: Active and passive mechanical properties of isolated arterioles from STZ-induced diabetic rats. Effect of aminoguanidine treatment. Diabetes (1994) 43(12):1450–1456.
  • YU G, ZOU H, PREWITT RL, HILL MA: Impaired arteriolar mechanotransduction in experimental diabetes mellitus. I Diabetes Complications (1999) 13(5-6):235–242.
  • RAJAH TT, OLSON AL, GRAMMAS P: Differential glucose uptake in retina- and brain-derived endothelial cells. Micro vasc. Res. (2001) 62(3):236–242.
  • KNOTT RM, ROBERTSON M, MUCKERSIE E, FORRESTER JV: Regulation of glucose transporters (GLUT-1 and GLUT-3) in human retinal endothelial cells. Biochem. J. (1996) 318(Pt 1):313–317.
  • LEC OUTER J, KOWALSKI J, FOSTER J et al.: Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature (2001) 412(6850):877–884.
  • CARMELIET P: Cardiovascular biology. Creating unique blood vessels. Nature (2001) 412(6850):868–869.
  • SOBEY CG: Potassium channel function in vascular disease. Arterioscler. Thromb. Vasc. Biol. (2001) 21(1):28–38.
  • KOHLER R, DEGENHARDT C, KUHN M et al: Expression and function of endothelial Ca(2-0-activated KH channels in human mesenteric artery: A single-cell reverse transcriptase-polymerase chain reaction and electrophysiological study in situ. Circ. Res. (2000) 87(6):496–503.
  • VAN KEMPEN MJ, JONGSMA HJ: Distribution of connexin37, connexin40 and connexin43 in the aorta and coronary artery of several mammals. Histochem. Cell Biol. (1999) 112(6):479–486.
  • SANDOW SL, HILL CE: Incidence of myoendothelial gap junctions in the proximal and distal mesenteric arteries of the rat is suggestive of a role in endothelium-derived hyperpolarizing factor-mediated responses. Circ.Res. (2000) 86(3):341–346.
  • OKU H, KODAMA T, SAKAGAMI K, PURO DG: Diabetes-induced disruption of gap junction pathways within the retinal microvasculature. Invest. Ophthalmol Vis. Sci. (2001) 42(8):1915–1920.
  • CHI JT, CHANG HY, HARALDSEN G et al: Endothelial cell diversity revealed by global expression profiling. Proc. Nat] Acad. Sci. USA (2003) 100(19):10623–10628.
  • •This paper provides evidence for fundamental differences in populations of endothelial cells obtained from various sites, including arterial, venous, macro- and microvasculature. DNA array methodology is used to suggest that heterogeneity between populations of endothelial cells may represent differences in programming.
  • PERRY MA, GRANGER DN: Role of CD11/CD18 in shear rate-dependent leukocyte-endothelial cell interactions in cat mesenteric venules. Clin. Invest. (1991) 87(5):1798–1804.
  • HENRY RIVI, FERREIRA I, KOSTENSE PJ et al.: Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation but impaired glucose metabolism is not; The Hoorn Study. Atherosclerosis (2004) 174(1):49–56.
  • BOULOUMIE A, MARUMO T, LAFONTAN M, BUSSE R: Leptin induces oxidative stress in human endothelial cells. Faseb/(1999) 13(10):1231–1238.
  • GOETZE S, BUNGENSTOCK A, CZUPALLA C et al.: Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension (2002) 40(5):748–754.
  • DUPUIS J, TARDIF JC, CERNACEK P, THEROUX P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischaemia and function of the endothelium) trial. Circulation (1999) 99(25):3227–3233.
  • JENKINS AJ, ROWLEY KG, LYONS TJ et al.: Lipoproteins and diabetic microvascular complications. Curr. Pharm. Des. (2004) 10(27):3395–3418.
  • ASSMANN G, GOTTO AM Jr: HDL cholesterol and protective factors in atherosclerosis. Circulation (2004) 109(23 Suppl. 1):1118–11114.
  • JIANG F, GUO Y, SALVEMINI D, DUSTING GJ: Superoxide dismutase mimetic M40403 improves endothelial function in apolipoprotein(E)-deficient mice. BE J. Pharmacol (2003) 139(6):1127–1134.
  • CAI H, HARRISON DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. (2000) 87(10):840–844.
  • PANZA JA, CASINO PR, KILCOYNE CM, QUYYUMI AA: Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation (1993) 87(5):1468–1474.
  • HIGASHI Y, YOSHIZUMI M: Exercise and endothelial function: role of endothelium-derived nitric oxide and oxidative stress in healthy subjects and hypertensive patients. Pharmacol Ther. (2004) 102(1):87–96.
  • BOHLEN HG, NASE GP: Obesity lowers hyperglycemic threshold for impaired in vivo endothelial nitric oxide function. Am. I Physiol Heart Circ. Physiol (2002) 283(1):H391–H397.
  • OZANNE SE, HALES CN: Early programming of glucose-insulinmetabolism. Trends Endocrinol. Metab. (2002) 13(9):368–373.
  • TAYLOR PD, KHAN TY, HANSON MA, POSTON L: Impaired EDHF-mediated vasodilatation in adult offspring of rats exposed to a fat-rich diet in pregnancy. Physiol. (2004) 558(Pt 3):943–951.
  • UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352(9131):837–853.
  • SHICHIRI M, KISHIKAWA H, OHKUBO Y, WAKE N: Long-term results of the Kumamoto Study on optimal diabetes control in Type 2 diabetic patients. Diabetes Care (2000) 23\(Suppl. 2):B21–B29.
  • MATHER KJ, VERMA S, ANDERSON TJ: Improved endothelial function with metformin in Type 2 diabetes mellitus. J. Am. Coll Cardiol. (2001) 37(5):1344–1350.
  • SEKIYA M, SUZUKI J, WATANABE K et al: Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus. fpn. Circ. J. (2001) 65(6):487–490.
  • VINIK Al, STANSBERRY KB, BARLOW PM: Rosiglitazone treatment increases nitric oxide production in human peripheral skin: a controlled clinical trial in patients with Type 2 diabetes mellitus. J. Diabetes Complications (2003) 17(5):279–285.
  • PISTROSCH F, PASSAUER J, FISCHER S et al: In Type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care (2004) 27(2):484–490.
  • YUSUF S, SLEIGHT P, POGUE J et al: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.N. Engl. J. Med. (2000) 342(3):145–153.
  • HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet (2000) 355(9200):253–259.
  • O'DRISCOLL G, GREEN D, RANKIN J, STANTON K, TAYLOR R: Improvement in endothelial function by angiotensin-converting enzyme inhibition in insulin-dependent diabetes mellitus. Clin. Invest. (1997) 100(3):678–684.
  • O'DRISCOLL G, GREEN D, MAIORANA A et al: Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. (1999) 33(6):1506–1511.
  • UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS39. Br. Med. 1 (1998) 317(7160):713–720.
  • CERIELLO A, MOTZ E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol. (2004) 24(5):816–823.
  • GOLDBERG RB, MELLIES MJ, SACKS FM et al: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation (1998) 98(23):2513–2519.
  • COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multi-centre randomised placebo-controlled trial. Lancet (2004) 364(9435):685–696.
  • COLLINS R, ARMITAGE J, PARISH S, SLEIGH P, PETO R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 361(9374):2005–2016.
  • RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl. I Med. (1999) 341(6):410–418.
  • DIABETES ATHEROSCLEROSIS INTERVENTION STUDY GROUP: Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet (2001) 357(9260):905–910.
  • ELKELES RS, DIAMOND JR, POULTER C et al: Cardiovascular outcomes in Type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care (1998) 21(4):641–648.
  • LAUFS U: Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur. I Clin. Pharmacol. (2003) 58(10:719–731.
  • DAVIGNON J: Beneficial cardiovascular pleiotropic effects of statins. Circulation (2004) 109(23 Suppl. 1) :11139–11143.
  • FONAROW GC, GAWLINSKI A, MOUGHRABI S, TILLISCH JH: Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Programme (CHAMP). Am. J. Cardiol. (2001) 87(7):819–822.
  • GAEDE P, VEDEL P, LARSEN N et al.: Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl. I Med. (2003) 348(5):383–393.
  • VINGOLO EM, DE MATTIA G, GIUSTI C et al: Treatment of nonproliferative diabetic retinopathy with Defibrotide in noninsulin-dependent diabetes mellitus: a pilot study. Acta Ophthalmol. Scand. (1999) 77(3):315–320.
  • BELCARO G, MARELLI C, POMANTE P et al: Fibrinolytic enhancement in diabetic microangiopathy with defibrotide. Angiology (1992) 43(10):793–800.
  • MORCOS M, BORCEA V, ISERMANN B et al: Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res. Pract. (2001) 52(3):175–183.
  • CINAR MG, ULKER S, ALPER G, EVINC A: Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats. Pharmacology (2001) 62(1):56–64.
  • SKYRME-JONES RA, O'BRIEN RC, BERRY KL, MEREDITH IT: Vitamin E supplementation improves endothelial function in Type I diabetes mellitus: a randomised, placebo-controlled study../. Am. Coll. Cardiol. (2000) 36(1):94–102.
  • WILLIAMS SB, GOLDFINE AB, TIMIMI FK et al.: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation (1998) 97(17):1695–1701.
  • ANTONIADES C, TOUSOULIS D, TENTOLOURIS C, TOUTOUZAS P, STEFANADIS C: Oxidative stress, antioxidant vitamins, and atherosclerosis. From basic research to clinical practice. Herz (2003) 28(7):628–638.
  • THE HOPE STUDY INVESTIGATORS: The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomised trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can. J. Cardiol. (1996) 12(2):127–137.
  • YUSUF S, DAGENAIS G, POGUE J, BOSCH J, SLEIGHT P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. J. Med. (2000) 342 (3): 154–160.
  • LONN E, YUSUF S, HOOGWERF B et al: Effects of vitamin Eon cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICROHOPE substudy. Diabetes Care (2002) 25(11):1919–1927.
  • MRC/BHF HEART PROTECTION STUDY GROUP: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360(9326):23–33.
  • HALLIWELL B: The antioxidant paradox. Lancet (2000) 355(9210):1179–1180.
  • HALLIWELL B, WHITEMAN M: Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? BE J. Pharmacol. (2004) 142 (2): 231–255.
  • BURSELL SE, CLERMONT AC, AIELLO LP et al: High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with Type 1 diabetes. Diabetes Care (1999) 22(8):1245–1251.
  • ANDERSON TJ: Assessment and treatment of endothelial dysfunction in humans. ./. Am. Coll Cardiol. (1999) 34(3):631–638.
  • AKAMINE EH, HOHMAN TC, NIGRO D et al.: Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. Pharmacol. Exp. Ther. (2003) 304(3):1236–1242.
  • GREENE DA, AREZZO JC, BROWN MB: Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology (1999) 53(3):580–591.
  • ASANO T, SAITO Y, KAWAKAMI M, YAMADA N: Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. J. Diabetes Complications (2002) 16(2):133–138.
  • THORNALLEY PJ: Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation end products. Arch. Biochem. Biophys. (2003) 419(1):31–40.
  • SHEN GX: Selective protein kinase C inhibitors and their applications. Curr. Drug Targets Cardiovasc. Haematol. Disord. (2003) 3(4):301–307.
  • WOLFFENBUTTEL BH, BOULANGER CM, CRIJNS FR et al.: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Nati Acad. Sci. USA (1998) 95(8):4630–4634.
  • VAITKEVICIUS PV, LANE M, SPURGEON H et al: A crosslink breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc. Natl. Acad. Sci. USA (2001) 98(3):1171–1175.
  • ASIF M, EGAN J, VASAN S et al: An advanced glycation end product crosslink breaker can reverse age-related increases in myocardial stiffness. Proc. Natl. Acad. Li. USA (2000) 97(6):2809–2813.
  • CANDIDO R, FORBES JM, THOMAS MC et al: A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res. (2003) 92(7):785–792.
  • FORBES JM, YEE LT, THALLAS V et al: Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes (2004) 53(7):1813–1823.
  • HOLLENBACH S, THAMPI P, VISWANATHAN T, ABRAHAM EC: Cleavage of in vitro and in vivo formed lens protein crosslinks by a novel crosslink breaker. Mol. Cell. Biochem. (2003) 243(1-2):73–80.
  • JERUMS G, PANAGIOTOPOULOS S, FORBES J, OSICKA T, COOPER M: Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. Arch. Biochem. Biophys. (2003) 419(1):55–62.
  • BEISSWENGER PJ, HOWELL SK, TOUCHETTE AD, LAL S, SZWERGOLD BS: Metformin reduces systemic methylglyoxal levels in Type 2 diabetes. Diabetes (1999) 48(1):198–202.
  • ZANETTI M, SATO J, KATUSIC ZS, O'BRIEN T: Gene transfer of endothelial nitric oxide synthase alters endothelium-dependent relaxations in aortae from diabetic rabbits. Diabetologia (2000) 43(3):340–347.
  • ZANETTI M, SATO J, KATUSIC ZS, O'BRIEN T: Gene transfer of superoxide dismutase isoforms reverses endothelial dysfunction in diabetic rabbit aorta. Am. J. Physiol. Heart Circ. Physiol. (2001) 280(6):H2516–2523.
  • LUND DD, FARACI FM, MILLER FJ Jr., HEISTAD DD: Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits. Circulation (2000) 101(9):1027–1033.
  • PANNIRSELVAM M, ANDERSON TJ, TRIGGLE CR: Characterization of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from diabetic (db/db -/-) mice. In: Proceedings of the Fourth International Workshop on Endothelium-Derived Hyperpolarizing Factor. Vanhoutte PM (Ed.), Taylor & Francis, London & New York (2003):124–131.
  • WIGG SJ, TARE M, TONTA MA et al.: Comparison of effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery. Am. J. Physiol. Heart Circ. Physiol. (2001) 281(1):H232–H240.
  • MATSUMOTO T, KOBAYASHI T, KAMATA K: Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am. J. Physiol. Heart Circ. Physiol. (2003) 285(1):H283–H291.
  • MATSUMOTO T, WAKABAYASHI K, KOBAYASHI T, KAMATA K: Alterations in vascular endothelial function in the aorta and mesenteric artery in Type II diabetic rats. Can. Physic] Pharmacol (2004) 82(3):175–182.
  • COLEMAN HA, TARE M, PARKINGTON HC: Endothelial potassium channels, endothelium-dependent hyperpolarization and the regulation of vascular tone in health and disease. Clin. Exp. Pharmacol Physic] (2004) 31(9):641–649.
  • PENA AS, WILTSHIRE E, GENT R, HIRTE C, COUPER J: Folic acid improves endothelial function in children and adolescents with Type 1 diabetes. J. Pediatr. (2004) 144(4):500–504.
  • VAN ETTEN RW, DE KONING EJ, VERHAAR MC, GAILLARD CA, RABELINK TJ: Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia (2002) 45(7):1004–1010.
  • WULFFELE MG, KOOY A, LEHERT P et al.: Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in Type 2 diabetes mellitus: a randomised, placebo-controlled trial../. Intern. Med. (2003) 254(5):455–463.

Websites

  • http://www.diabetes.org/diabetes-statistics/heart-diseasejsp American Diabetes Assosciation Website, Diabetes and cardiovascular (heart) disease statistics (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.